Beike Biotech Acquires Altor's Cancer Drug in $200 Million Deal

Shenzhen Beike Biotechnology acquired China rights to a novel cancer immunotherapy developed by Altor BioScience of Florida. ALT-803 is Altor’s proprietary Interleukin-15 (IL-15) based superagonist complex that is currently in four US Phase I/II clinical trials for various indications. Beike made an upfront payment of $4 million and invested another $5 million in Altor. Beike also agreed to a package of over $200 million in development and sales milestones and will pay a tiered double-digit royalty on sales. More details.... Share this with colleagues: // //